Lipidor AB (publ) (LIPI)の価格はいくらですか

Lipidor AB (publ) (LIPI)の価格は$0.02243487です

Lipidor AB (publ) (LIPI)の時価総額は何ですか

Lipidor AB (publ) (LIPI)の時価総額は$650.09Kです

Lipidor AB (publ)（LIPI）営業利益率

Lipidor AB (publ), a Swedish pharmaceutical company founded in Danderyd in 2009, specializes in developing medicinal products. Its core business centers on creating treatments for various skin conditions, including psoriasis, bacterial skin infections, and atopic dermatitis. The company's product pipeline includes AKP-01, which is currently in Phase III clinical trials for psoriasis, while other formulations like AKP-02 (also for psoriasis) and AKP-03 and AKP-07 (for eczema) are in earlier, preclinical development stages. Beyond its own drug candidates, Lipidor manufactures and supplies active pharmaceutical ingredients (APIs). These APIs are incorporated into products addressing a broad spectrum of therapeutic applications, such as managing psoriasis, microbial infections, inflammation, fungal issues, local pain relief, acne, wound healing, eczema, and migraines. Lipidor also caters to the animal health market, offering a line of spray-on skin care products for dogs, cats, and horses. Additionally, it develops consumer health items designed for purposes like antibacterial action, antiseptic care, moisturizing, disinfection, and treating acne and warts. In a key strategic alliance, Lipidor has partnered with Cannassure Therapeutics Ltd. This collaboration aims to advance topical medicinal cannabis products specifically formulated to alleviate skin inflammations and psoriatic lesions.

年	営業利益率	変化
2026 (TTM)	-101,500.00%	0.00%
2024	-101,500.00%	412.29%
2023	-19,812.82%	-78.50%
2022	-92,155.56%	66,165.59%
2021	-139.07%	-94.70%
2020	-2,623.23%	-86.32%
2019	-19,177.78%	510.45%
2018	-3,141.56%	240.80%
2017	-921.82%	-46.73%
2016	-1,730.46%	0.00%

年

営業利益率

変化

2026 (TTM)

-101,500.00%

0.00%

2024

-101,500.00%

412.29%

2023

-19,812.82%

-78.50%

2022

-92,155.56%

66,165.59%

2021

-139.07%

-94.70%

2020

-2,623.23%

-86.32%

2019

-19,177.78%

510.45%

2018

-3,141.56%

240.80%

2017

-921.82%

-46.73%

2016

-1,730.46%

0.00%

企業	営業利益率	営業利益率の差	国
Eli Lilly and Company LLY.US	45.87%	-100.00%	US
Johnson & Johnson JNJ.US	26.81%	-100.00%	US
AbbVie Inc. ABBV.US	27.60%	-100.00%	US
Roche Holding AG RO.SW	26.59%	-100.00%	CH
Merck & Co., Inc. MRK.US	27.59%	-100.00%	US

企業

営業利益率

営業利益率の差

国